The aftercare principle for metastasizing prostate cancer - Little diagnostics much support;Das nachsorgeprinzip beim metastasierten prostatakarzinom - Wenig diagnostik, viel support

Urologe - Ausgabe A

Volumn 44, Issue 9, 2005, Pages 1009-1017

  Heine, K ^a   Wolff, J M ^a,b  

^a Urologische Klinik   (Germany)

^b Caritaskrankenhaus   (Germany)

Author keywords

Aftercare; Complications; Prostate cancer; Recognition of progression

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AFTERCARE; ANEMIA; ARTICLE; BONE DISEASE; CANCER DIAGNOSIS; CANCER GROWTH; DIAGNOSTIC PROCEDURE; ENVIRONMENT; HUMAN; METASTASIS; PAIN; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT FAILURE;

AFTERCARE; BONE NEOPLASMS; CARCINOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TERMINAL CARE; TREATMENT OUTCOME;

EID: 24944450963     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0885-6     Document Type: Article

References (49)

1. Algra PR, Bloem JL, Tissing H, Falke TH, Arndt JW, Verboom LJ (1991) Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 11(2): 219-232
2. Coleman RE, Ourohit OP, Vinholes JJ, Zekri J (1997) High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80: 1652-1660
3. Dearnaley DP, Sydes MR, Mason MD et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO Trial). J Natl Cancer Inst 95: 1300-1311
4. Diamond TH, Winters J, Smith A et al. (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 92: 1444-1450
5. Dunst J, Kuhnt T et al. (2003) Anaemia in cervical cancers: patterns of relapse and association with tumor hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56(3): 778-787
6. Dupont A, Cusan L et al. (1991) Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol 146: 1064-1067
7. Ercole CJ, Lange PH et al. (1987) Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 138: 1181-1184
8. Flynn DF, Shipley WU (1991) Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am 18(1): 145-152
9. Frommhold H, Guttenberger R, Henke M (1998) The impact of blood haemoglobin content on the outcome of radiotherapy. Strahlenther Onkol 174[Suppl IV]: 31-34
10. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98(3): 259-260
11. Grogan M, Thomas GM et al. (1999) The importance of maintaining high hemoglobin levels during radiation treatment of the carcinoma of the cervix. Cancer 86: 1531-1536
12. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165: 136-140
13. Henke M, Laszig R, Rube C et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362(9392): 1255-1260
14. Huddart RA, Rajan B, Law M, Meyer L, Dearnaley DP (1997) Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol 44(3): 229-236
15. Iacovou JW, Marks JC, Abrams PH, Gingell JC, Ball AJ (1985) Cord compression and carcinoma of the prostate: is laminectomy justified? Br J Urol 57(6): 733-736
16. Kelly WK, Scher HI, Mazumdar M et al. (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615
17. Kuban DA, El-Mahdi AM, Sigfred SV (1986) Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology 18: 364-369
18. Leo ME, Bilhartz DL, Bergstralh, Oesterling JE (1991) Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 145: 802-806
19. Lipton A, Glover D, Harvey H et al. (1994) Pamidronate in the treatment of bone metastases: results of 2 dose ranging trials in patients with breast and prostate cancer. Ann Oncol 5: S31-S35
20. Lissoni P, Rovelli F et al. (2001) A Pase II study of s.c.low-dose IL2 plus Erythropoietin in metastatic renal cell carcinoma progressing on IL2 allone. Anticancer Res 21: 777-779
21. Littlewood TJ, Bajetta E et al. (2001) Effects of epoetin alfa on heamatologic parameters and qualità of life in cancer patients receiving nonplatinum chemotherapy. J Clin Oncol 19: 2865-2874
22. Messing EM, Thompson I Jr (2003) Follow Up of conservatively managed prostate cancer - wachtful waiting and primary hormonal therapy. Urol Clin N Am 30: 687-702
23. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 104: 83-93
24. Mittelman M, Zeidman A et al. (2004) Erythropoietin has an antimyeloma effect - a hypothesis based on a clinical observation supported by animal studys. Eur J Haematol 72: 155-165
25. Modic MT, Masaryk T, Paushter D (1986) Magnetic resonance imaging of the spine. Radiol Clin North Am 24(2): 229-245
26. Nowrousian MR (2000) Pathophysiologie der tumorbedingten oder chemotherapieinduzierten Anämie. In: Nowrousian MR (Hrsg) Supportive Therapie in der Onkologie. Zuckschwerdt, München, S 84-98
27. Nowrousian MR (2002) Pathophysiology of cancer related anaemia. In: Nowrousian MR (ed) Recombinant Human Erythropoietin(rhEPO) in clinical oncology - scientific and clinical aspects of anaemia in cancer. Springer, Wien, pp 39-62
28. Oefelein MG, Richuiti V, Conrad W et al. (2001) Skeletal fracture rate associated with androgen supression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724-1728
29. Österborg A, Brandberg Y et al. (2002) Randomized double-blind, placebo controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494
30. Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. New Engl J Med 343: 604-610
31. Osborn JL, Getzenberg RH, Trump DL (1995) Spinal cord compression in prostate cancer. J Neurooncol 23: 135-147
32. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone refractory prostate cancer treated with single-agent chemotherapy. Cancer 70(12): 2870-2878
33. Rubin H, Lome LG, Presman D (1974) Neurological manifestations of metastatic prostate carcinoma. J Urol 111: 799-802
34. Rubins J (1995) Metastatic renal cell carcinoma: response to treatment with human recombinant erythropoietin. Ann Intern Med 122: 676-677
35. Rudat V, Dietz A et al. (1999) Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 53: 119-125
36. Saad F, Gleason DM, Murray R et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468
37. Silver DF, Piver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer. Gynecol Oncol 73: 280-284
38. Smith DC, Vogelzang NJ, Goldberg HL et al. (1993) High dose cyclophosphamide (CTX) with granulocyte-macrophage stimulating factor (GM-CSF) in hormone refractory prostate carcinoma. Proc Am Soc Clin Oncol 11: 213
39. Smith JA Jr, Lange PH et al. (1997) Serum markers as apredictor of response duration and patients survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 157: 1329-1334
40. Smith MR (2002) Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21: 159-166
41. Smith MR, McGovern FJ, Zietman AL et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New Engl J Med 345: 989-991
42. Smith M et al. (2003) Randomised controlled trial of zoledronic acid to prevent boneloss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008-2012
43. Smith MR, Eastham J, Gleason DM et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 170: 2392-2393
44. Stüben G, Thews O, Pottgen C et al. (2001) Recombinant Human Erythropoietin increases the radiosensitivity of xenografted human tumors in anaemic nude mice. J Cancer Res Clin Oncol 127: 346-350
45. Tarnawski R, Skladowski K et al. (1997) Prognostic value of hemoglobin concentration in radiotherapy for cancer of the supraglottic larynx. Int Radiat Oncol Biol Phys 38: 1007-1011
46. Thews O, König R et al. (1998) Enhanced radiosensitivity in experimental tumors following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78: 752-56
47. Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anaemia-induced reduction in cyclophosphamid toxicity in rat tumors. Cancer Res 61: 1358-1361
48. Werner-Wasik M, Scott C, Cox JD et al. (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patient swith locally advanced non-small-cell-lung cancer (LA-NSCLC): identification of 5 groups with different survival, Int Radiat Oncol Biol Phys 48: 1475-1482
49. Yao Siu-Long, DiPaola RS (2003) An evidence-based approach to prostate cancer follow-up. Semin Oncol 30(3): 390-400